Competing interests
Janssen/Roche
EVENTS
O.A.S. reports personal fees and honoraria from AbbVie, Adaptive, Ascentage, AstraZeneca, BeiGene, Genmab, Gilead, Janssen, Eli Lilly and Roche; and research funding from AbbVie, BeiGene, Janssen and Roche. A.M.F. received research funding from Celgene; is on the advisory board of Janssen; and received travel grants from AbbVie. E.T. reports advisory board (AbbVie, Janssen-Cilag and BeiGene), speaker honoraria (AstraZeneca, AbbVie, BeiGene, Gilead, Janssen and Roche) and research funding (Roche, AbbVie and Gilead). C.S. reports speaker honoraria (AstraZeneca and AbbVie). S.B. received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Roche, AbbVie, Novartis, Becton Dickinson, Janssen, AstraZeneca and Sanofi; and received grants or contracts from Janssen-Cilag. M.R. reports grants from F. Hoffman-La Roche; and personal fees from F. Hoffmann-La Roche and AbbVie. J.S. reports consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, AbbVie and Sanofi. J.v.T. received research support from Janssen/Roche; received travel grants from AbbVie, Janssen, Roche and Celgene; received honoraria from Roche, Janssen, AbbVie and AstraZeneca; and is on the advisory boards of Janssen, Roche and AbbVie. C.M.W. reports grants and personal fees from Janssen-Cilag during the conduct of the study; and grants and personal fees from Janssen-Cilag, Hoffmann-La Roche, AbbVie and Gilead outside the submitted work. K.F. reports honoraria by AbbVie and Roche and is an advisor for AstraZeneca. B.C. reports grants from Gilead Sciences and personal fees and honoraria from Janssen, F. Hoffmann-La Roche, AstraZeneca, AbbVie, BMS, Gilead, Sobi and Incyte. K.A.K. reports grants from F. Hoffmann-La Roche and AbbVie, during the conduct of the study; and personal fees from F. Hoffmann-La Roche and AbbVie. S.S. received advisory board honoraria, research support, travel support and speaker fees from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann-La Roche, Janssen, Novartis and Sunesis. P.S. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Takeda, Bristol Myers Squibb, Novartis, BeiGene, Incyte, GlaxoSmithKline, Janssen, Roche, MedMedia, AstraZeneca, AbbVie, Amgen, Medahead, Sanofi and Merck Sharp & Dome. C.N. received research funding from Novo Nordisk Foundation grant NF16OC0019302 and research support, consultancy fees and/or travel grants from AbbVie, Gilead, Janssen, Roche, CSL Behring, Genmab, Sunesis and Acerta/AstraZeneca. M.H. is an advisor or consultant for Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie and AstraZeneca and reports honoraria from Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie and AstraZeneca. A.-M.F. reports research funding by AstraZeneca and Celgene and travel support by AbbVie. B.E. is an advisor or consultant for Janssen, AbbVie, Kite, AstraZeneca, MSD and Miltenyi and received honoraria from Janssen, Roche, AbbVie, Lilly, Kite, AstraZeneca, BeiGene and MSD; and reports research funding by Janssen, Gilead, Roche, AbbVie, BeiGene and AstraZeneca. The remaining authors declare no competing interests.